Tags

Type your tag names separated by a space and hit enter

Effect of rosiglitazone on insulin resistance, growth factors, and reproductive disturbances in women with polycystic ovary syndrome.
Fertil Steril. 2004 Mar; 81(3):624-9.FS

Abstract

OBJECTIVE

To evaluate the effects of rosiglitazone on insulin resistance, growth factors, and reproductive disturbances in women with polycystic ovary syndrome (PCOS).

DESIGN

Prospective study.

SETTING

Women with PCOS attending as outpatients of the Endocrine Division, Hospital Durand, Buenos Aires.

PATIENT(S)

Twenty-four insulin-resistant women with PCOS.

INTERVENTION(S)

Hormonal evaluations and a standardized oral glucose tolerance test before and after a 3-month trial of 4 mg of rosiglitazone daily.

MAIN OUTCOME MEASURE(S)

Serum LH, FSH, T, IGF-1, IGFBP-1, IGFBP-3, leptin, 17alpha-hydroxyprogesterone, insulin, and glucose concentrations. The area under insulin curve (AUC-insulin), the HOMA index (insulin resistance), the QUICKI index (insulin sensitivity), and the beta-cell function were calculated. Body mass index (BMI) and the waist/hip ratio were evaluated.

RESULT(S)

A significant decrease was observed in serum fasting insulin, AUC insulin, HOMA index, beta-cell function, IGF-1, LH, and waist/hip ratio. The QUICKI index and IGFBP-1 increased significantly. Serum sex hormone-binding globulin, androgens, leptin, IGFBP-3, and BMI remained unchanged. Twenty-two of 23 females had their menses restored, and three patients became pregnant. One patient was excluded because she became pregnant at the second month.

CONCLUSION(S)

Associated with the decrease in LH, rosiglitazone improved insulin-resistance parameters and normalized the menstrual cycle, which suggests that this drug could improve the endocrine-reproductive condition in insulin-resistant women with PCOS.

Authors+Show Affiliations

Endocrine Division, Hospital Carlos Durand, Buenos Aires, Argentina.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Controlled Clinical Trial
Journal Article

Language

eng

PubMed ID

15037412

Citation

Belli, Susana H., et al. "Effect of Rosiglitazone On Insulin Resistance, Growth Factors, and Reproductive Disturbances in Women With Polycystic Ovary Syndrome." Fertility and Sterility, vol. 81, no. 3, 2004, pp. 624-9.
Belli SH, Graffigna MN, Oneto A, et al. Effect of rosiglitazone on insulin resistance, growth factors, and reproductive disturbances in women with polycystic ovary syndrome. Fertil Steril. 2004;81(3):624-9.
Belli, S. H., Graffigna, M. N., Oneto, A., Otero, P., Schurman, L., & Levalle, O. A. (2004). Effect of rosiglitazone on insulin resistance, growth factors, and reproductive disturbances in women with polycystic ovary syndrome. Fertility and Sterility, 81(3), 624-9.
Belli SH, et al. Effect of Rosiglitazone On Insulin Resistance, Growth Factors, and Reproductive Disturbances in Women With Polycystic Ovary Syndrome. Fertil Steril. 2004;81(3):624-9. PubMed PMID: 15037412.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effect of rosiglitazone on insulin resistance, growth factors, and reproductive disturbances in women with polycystic ovary syndrome. AU - Belli,Susana H, AU - Graffigna,Mabel N, AU - Oneto,Adriana, AU - Otero,Patricia, AU - Schurman,Leon, AU - Levalle,Oscar A, PY - 2003/04/23/received PY - 2003/08/04/revised PY - 2003/08/04/accepted PY - 2004/3/24/pubmed PY - 2004/4/29/medline PY - 2004/3/24/entrez SP - 624 EP - 9 JF - Fertility and sterility JO - Fertil. Steril. VL - 81 IS - 3 N2 - OBJECTIVE: To evaluate the effects of rosiglitazone on insulin resistance, growth factors, and reproductive disturbances in women with polycystic ovary syndrome (PCOS). DESIGN: Prospective study. SETTING: Women with PCOS attending as outpatients of the Endocrine Division, Hospital Durand, Buenos Aires. PATIENT(S): Twenty-four insulin-resistant women with PCOS. INTERVENTION(S): Hormonal evaluations and a standardized oral glucose tolerance test before and after a 3-month trial of 4 mg of rosiglitazone daily. MAIN OUTCOME MEASURE(S): Serum LH, FSH, T, IGF-1, IGFBP-1, IGFBP-3, leptin, 17alpha-hydroxyprogesterone, insulin, and glucose concentrations. The area under insulin curve (AUC-insulin), the HOMA index (insulin resistance), the QUICKI index (insulin sensitivity), and the beta-cell function were calculated. Body mass index (BMI) and the waist/hip ratio were evaluated. RESULT(S): A significant decrease was observed in serum fasting insulin, AUC insulin, HOMA index, beta-cell function, IGF-1, LH, and waist/hip ratio. The QUICKI index and IGFBP-1 increased significantly. Serum sex hormone-binding globulin, androgens, leptin, IGFBP-3, and BMI remained unchanged. Twenty-two of 23 females had their menses restored, and three patients became pregnant. One patient was excluded because she became pregnant at the second month. CONCLUSION(S): Associated with the decrease in LH, rosiglitazone improved insulin-resistance parameters and normalized the menstrual cycle, which suggests that this drug could improve the endocrine-reproductive condition in insulin-resistant women with PCOS. SN - 0015-0282 UR - https://www.unboundmedicine.com/medline/citation/15037412/Effect_of_rosiglitazone_on_insulin_resistance_growth_factors_and_reproductive_disturbances_in_women_with_polycystic_ovary_syndrome_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0015028203030243 DB - PRIME DP - Unbound Medicine ER -